The use of the Capability Approach in health economic evaluations
Paul Mitchell, Senior Research Associate, Health Economics at Bristol (HEB), University of Bristol
Wednesday, 06 December 2017, 12pm to 1pm
University of Oxford Old Road Campus, Richard Doll Building OX3 7LF
Hosted by HERC
Abstract: The Capability Approach initiated by Nobel Prize winning economist, Amartya Sen has inspired the development of a number of outcome measures of patient benefit for use in health economic evaluations. Capability measures are becoming increasingly recognised as useful measures in health economics and some measures are now considered by NICE to inform treatment decisions. In this talk, Paul Mitchell will give an overview of the current capability measures available and provide some suggestions on how to use these measures in economic evaluation, with particular emphasis given to the ICECAP capability measures. He will also discuss some preliminary findings from his ongoing research involving a think aloud study, which aims to explore face validity, feasibility of completion and acceptability of the EQ-5D-5L, ICECAP-A and ICECAP-O measures in renal patients and to determine which ICECAP measure is more appropriate for this patient group. Finally, he will highlight further developments in the use of capability measures in health economics and future directions for research.
Short Bio: Paul Mitchell is a Senior Research Associate in health economics at the University of Bristol. Previously he worked at King’s College London with Dr Sridhar Venkatapuram, a leading philosopher in the Capability Approach and with Professor Joanna Coast at the University of Birmingham (now at Bristol), the lead developer of the ICECAP measures. Throughout his PhD and post-doctoral research, Paul has over seven years of research experience focusing on the use of the Capability Approach in health economics, dealing with the theoretical and the practical challenges involved. He has published this research in several leading academic journals, including Medical Decision Making, PharmacoEconomics, PLOS ONE and Social Science & Medicine.